<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Interface Biologics Inc</title> <link>https://www.globenewswire.com/rssfeed/organization/yMy9JqRR92MVI5cyzpozZw==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2018, Interface Biologics Inc</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Tue, 04 Dec 2018 13:00:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/04/1661590/0/en/Interface-Biologics-Announces-New-V-P-Business-Development.html</guid> <link>https://www.globenewswire.com/news-release/2018/12/04/1661590/0/en/Interface-Biologics-Announces-New-V-P-Business-Development.html</link> <title>Interface Biologics Announces New V.P., Business Development</title> <description><![CDATA[<p align="justify">TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the addition of Kelley Dealhoy, to the IBI management team, as Vice President of Business Development.</p>]]></description> <pubDate>Tue, 04 Dec 2018 13:00 GMT</pubDate> <dc:identifier>1661590</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc</dc:contributor> <dc:modified>Tue, 04 Dec 2018 13:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>Medical Device</dc:keyword> <dc:keyword>MedTech</dc:keyword> <dc:keyword>Pharmaceutical</dc:keyword> <dc:keyword>Drug Delivery</dc:keyword> <dc:keyword>Ophthalmology</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/27/1657382/0/en/Interface-Biologics-Completes-Pre-IND-Meeting-with-U-S-FDA-on-Epidel-Technology-for-treatment-of-Posterior-Inflammatory-Eye-Diseases.html</guid> <link>https://www.globenewswire.com/news-release/2018/11/27/1657382/0/en/Interface-Biologics-Completes-Pre-IND-Meeting-with-U-S-FDA-on-Epidel-Technology-for-treatment-of-Posterior-Inflammatory-Eye-Diseases.html</link> <title>Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases</title> <description><![CDATA[<p align="left">TORONTO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce a positive pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases. </p>]]></description> <pubDate>Tue, 27 Nov 2018 13:00 GMT</pubDate> <dc:identifier>1657382</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc</dc:contributor> <dc:modified>Tue, 27 Nov 2018 13:02 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>MedTech</dc:keyword> <dc:keyword>Pharmaceutical</dc:keyword> <dc:keyword>Eye Disease</dc:keyword> <dc:keyword>Ophthalmology</dc:keyword> <dc:keyword>Medical Device</dc:keyword> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/09/1066930/0/en/Interface-Biologics-Announces-the-Extension-of-its-Licensing-Agreement-with-Fresenius-Medical-Care.html</guid> <link>https://www.globenewswire.com/news-release/2016/02/09/1066930/0/en/Interface-Biologics-Announces-the-Extension-of-its-Licensing-Agreement-with-Fresenius-Medical-Care.html</link> <title>Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care</title> <description><![CDATA[<p><strong>TORONTO, CANADA--(Marketwired - Feb. 9, 2016) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (FRANKFURT:FME)(NYSE:FMS), the worlds' largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).</p>]]></description> <pubDate>Tue, 09 Feb 2016 12:30 GMT</pubDate> <dc:identifier>1066930</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.;Fresenius Medical Care</dc:contributor> <dc:modified>Tue, 12 Sep 2017 12:02 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2015/01/13/1436229/0/en/Interface-Biologics-Announces-Series-B-Financing-Round-With-DSM-and-BDC-Capital.html</guid> <link>https://www.globenewswire.com/news-release/2015/01/13/1436229/0/en/Interface-Biologics-Announces-Series-B-Financing-Round-With-DSM-and-BDC-Capital.html</link> <title>Interface Biologics Announces Series B Financing Round With DSM and BDC Capital</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) -</strong> Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital. </p>]]></description> <pubDate>Tue, 13 Jan 2015 12:30 GMT</pubDate> <dc:identifier>1436229</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2014/01/14/1436222/0/en/Interface-Biologics-and-Q3-Medical-Devices-Sign-Agreement-to-Develop-Next-Generation-Drug-Coated-Balloon-with-Kinesyx-TM-Technology.html</guid> <link>https://www.globenewswire.com/news-release/2014/01/14/1436222/0/en/Interface-Biologics-and-Q3-Medical-Devices-Sign-Agreement-to-Develop-Next-Generation-Drug-Coated-Balloon-with-Kinesyx-TM-Technology.html</link> <title>Interface Biologics and Q3 Medical Devices Sign Agreement to Develop Next Generation Drug Coated Balloon with Kinesyx(TM) Technology</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwired - Jan. 14, 2014) -</strong> Interface Biologics Inc. (IBI), and Q3 Medical Devices Limited are pleased to announce the signing of a joint development and commercialization agreement to combine IBI's Kinesyx bioactive oligomers with the balloon technology of Q3 Medical Devices wholly owned subsidiary, Qualimed Innovative Medizinprodukte GmbH, to create a next generation drug coated balloon for both coronary and peripheral applications.</p>]]></description> <pubDate>Tue, 14 Jan 2014 12:30 GMT</pubDate> <dc:identifier>1436222</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2013/03/05/1436217/0/en/Interface-Biologics-CSO-Paul-Santerre-receives-NSERC-Synergy-Innovation-Award-from-Governor-General.html</guid> <link>https://www.globenewswire.com/news-release/2013/03/05/1436217/0/en/Interface-Biologics-CSO-Paul-Santerre-receives-NSERC-Synergy-Innovation-Award-from-Governor-General.html</link> <title>Interface Biologics' CSO Paul Santerre receives NSERC Synergy Innovation Award from Governor General</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwire - March 5, 2013) -</strong> </p>]]></description> <pubDate>Tue, 05 Mar 2013 12:30 GMT</pubDate> <dc:identifier>1436217</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2012/10/02/1436212/0/en/Interface-Biologics-Appoints-Sandra-Beach-Lin-to-Board-of-Directors.html</guid> <link>https://www.globenewswire.com/news-release/2012/10/02/1436212/0/en/Interface-Biologics-Appoints-Sandra-Beach-Lin-to-Board-of-Directors.html</link> <title>Interface Biologics Appoints Sandra Beach Lin to Board of Directors</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwire - Oct. 2, 2012) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors. Ms. Beach Lin is an experienced C-suite executive with a wealth of polymer experience in multiple industries, including medical devices.</p>]]></description> <pubDate>Tue, 02 Oct 2012 11:30 GMT</pubDate> <dc:identifier>1436212</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2012/09/06/1436209/0/en/Interface-Biologics-Announces-Licensing-Partner-AngioDynamics-has-Received-FDA-Clearance-for-BioFlo-TM-PICC-with-Endexo-TM-Technology.html</guid> <link>https://www.globenewswire.com/news-release/2012/09/06/1436209/0/en/Interface-Biologics-Announces-Licensing-Partner-AngioDynamics-has-Received-FDA-Clearance-for-BioFlo-TM-PICC-with-Endexo-TM-Technology.html</link> <title>Interface Biologics Announces Licensing Partner AngioDynamics has Received FDA Clearance for BioFlo(TM) PICC with Endexo(TM) Technology</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwire - Sept. 6, 2012) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that AngioDynamics has been granted 510(k) clearance by the U.S. Food and Drug Administration for its BioFlo PICC with IBI's Endexo technology. These vascular access products are expected to launch in the U.S. in the next 30 days and are currently CE marked for Europe and approved in Canada and other international markets. Following its acquisition of Navilyst Medical earlier this year, Angiodynamics now has an exclusive license to incorporate IBI's Endexo technology in its PICCs, ports and dialysis catheter products. </p>]]></description> <pubDate>Thu, 06 Sep 2012 11:30 GMT</pubDate> <dc:identifier>1436209</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2011/10/25/1436204/0/en/Interface-Biologics-Announces-Licensing-Agreement-With-Navilyst-Medical.html</guid> <link>https://www.globenewswire.com/news-release/2011/10/25/1436204/0/en/Interface-Biologics-Announces-Licensing-Agreement-With-Navilyst-Medical.html</link> <title>Interface Biologics Announces Licensing Agreement With Navilyst Medical</title> <description><![CDATA[<p><strong>TORONTO, CANADA--(Marketwire - Oct. 25, 2011) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce a definitive license and supply agreement with Navilyst Medical, a leading manufacturer of image-guided medical technologies. Under this agreement, Navilyst Medical has exclusive access to incorporate IBI's Endexo™ technology in its vascular access products.</p>]]></description> <pubDate>Tue, 25 Oct 2011 12:30 GMT</pubDate> <dc:identifier>1436204</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2011/07/12/1436200/0/en/Fresenius-Medical-Care-Executes-Exclusive-Interface-Biologics-License-Agreement.html</guid> <link>https://www.globenewswire.com/news-release/2011/07/12/1436200/0/en/Fresenius-Medical-Care-Executes-Exclusive-Interface-Biologics-License-Agreement.html</link> <title>Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwire - July 12, 2011) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (NYSE:FMS), the world's largest integrated provider of dialysis products and services, has executed their option of an exclusive licensing agreement following a successful evaluation period.</p>]]></description> <pubDate>Tue, 12 Jul 2011 12:30 GMT</pubDate> <dc:identifier>1436200</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2011/02/14/1436197/0/en/Interface-Biologics-Appoints-Art-Rosenthal-to-Chairman-of-its-Board-of-Directors.html</guid> <link>https://www.globenewswire.com/news-release/2011/02/14/1436197/0/en/Interface-Biologics-Appoints-Art-Rosenthal-to-Chairman-of-its-Board-of-Directors.html</link> <title>Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors</title> <description><![CDATA[<p><strong>TORONTO, ONTARIO--(Marketwire - Feb. 14, 2011) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Arthur L. Rosenthal to Chairman of its Board of Directors. </p>]]></description> <pubDate>Mon, 14 Feb 2011 13:31 GMT</pubDate> <dc:identifier>1436197</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2011/01/10/1436192/0/en/Interface-Biologics-Announces-7M-Financing.html</guid> <link>https://www.globenewswire.com/news-release/2011/01/10/1436192/0/en/Interface-Biologics-Announces-7M-Financing.html</link> <title>Interface Biologics Announces $7M Financing</title> <description><![CDATA[<p><strong>TORONTO, CANADA--(Marketwire - Jan. 10, 2011) -</strong> Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the completion of a $7M series B financing, led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners. </p>]]></description> <pubDate>Mon, 10 Jan 2011 13:01 GMT</pubDate> <dc:identifier>1436192</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Interface Biologics Inc.</dc:contributor> <dc:modified>Thu, 15 Mar 2018 03:14 GMT</dc:modified> </item> </channel> </rss>